Sandoz Group (OTCMKTS:SDZNY) Upgraded to “Strong-Buy” at Barclays

Posted by on May 6th, 2026

Barclays upgraded shares of Sandoz Group (OTCMKTS:SDZNY – Free Report) from a hold rating to a strong-buy rating in a report published on Tuesday,Zacks.com reports.

A number of other brokerages have also recently weighed in on SDZNY. Jefferies Financial Group raised shares of Sandoz Group from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 12th. The Goldman Sachs Group raised Sandoz Group to a “strong-buy” rating in a report on Wednesday, April 1st. Finally, Royal Bank Of Canada cut Sandoz Group from a “moderate buy” rating to a “hold” rating in a research report on Monday, March 23rd. Three research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Strong Buy”.

Check Out Our Latest Stock Analysis on SDZNY

Sandoz Group Trading Up 5.3%

Shares of OTCMKTS:SDZNY opened at $84.29 on Tuesday. The firm has a 50 day simple moving average of $81.61 and a 200-day simple moving average of $76.13. Sandoz Group has a twelve month low of $44.02 and a twelve month high of $94.15. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.77 and a current ratio of 1.18.

Sandoz Group Company Profile

(Get Free Report)

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.

Further Reading

Receive News & Ratings for Sandoz Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sandoz Group and related companies with MarketBeat.com's FREE daily email newsletter.